Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278315 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cellectar Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02278315: Completed Phase 1 study, sponsored by Cellectar Biosciences.
NCT02278315 is a Phase 1 study that has completed, run by Cellectar Biosciences. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02278315, a Phase 1 study, has completed, sponsored by Cellectar Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.
Primary Outcome
DLT will be assessed by physical examination, vital signs, ECG, and laboratory values
Interventions
- DRUG dexamethasone
- DRUG I-131-CLR1404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-02 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 1 |
What the finished NCT02278315 record still lists
NCT02278315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT02278315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02278315 about?
NCT02278315 is a clinical study titled "Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma". The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an imm...
What is the current status of trial NCT02278315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2015-02. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT02278315?
The interventions under investigation include: dexamethasone (DRUG), I-131-CLR1404 (DRUG).
Who is sponsoring clinical trial NCT02278315?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02278315's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia